Assertio Holdings Inc
ASRT
Company Profile
Business description
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Contact
100 South Saunders Road
Suite 300
Lake ForestIL60045
USAT: +1 224 419-7106
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
30
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
AI stocks flew high in 2025 despite year-end volatility. Palantir and Lam look overvalued, but opportunities remain.
stocks
12 picks for an income portfolio - Q4 2025 update
Eighteen months in and passive income growth has exceeded my target.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,080.40 | 13.20 | 0.15% |
| CAC 40 | 8,362.09 | 118.63 | 1.44% |
| DAX 40 | 25,261.64 | 134.18 | 0.53% |
| Dow JONES (US) | 49,504.07 | 237.96 | 0.48% |
| FTSE 100 | 10,124.60 | 79.91 | 0.80% |
| HKSE | 26,283.57 | 51.78 | 0.20% |
| NASDAQ | 23,671.35 | 191.33 | 0.81% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,689.60 | 6.65 | -0.05% |
| S&P 500 | 6,966.28 | 44.82 | 0.65% |
| S&P/ASX 200 | 8,747.00 | 13.40 | 0.15% |
| SSE Composite Index | 4,127.40 | 6.97 | 0.17% |